title: [Statement on the use of mycophenolate mofetil for systemic lupus erythematosus].
abstract: Mycophenolate mofetil (MMF) is among the few immunosuppressive drugs with sufficient data from controlled studies on the therapy of systemic lupus erythematosus (SLE). In the light of results from recently published randomized controlled trials on the effectiveness of MMF in the treatment of lupus nephritis, it has become necessary to revise the statement of the Germany Society of Rheumatology on the use of MMF for SLE. In the induction therapy of lupus nephritis MMF has been shown to be equivalent in effectiveness to i.v. cyclophosphamide and superior to azathioprine in the maintenance phase. Cyclophosphamide is inferior to MMF and probably also to azathioprine as maintenance therapy and should therefore, not be considered for this purpose and also because of its toxicity. For other organ manifestations MMF also constitutes an alternative when approved immunosuppressants are not able to control the disease and glucocorticoids cannot be reduced to 7.5 mg prednisolone daily equivalents or less.
authors.affiliation: Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Fetscherstr. 74, 01307, Dresden, Deutschland. martin.aringer@uniklinikum-dresden.de
authors.forename: M
authors.initials: M
authors.lastname: Aringer
authors.forename: R
authors.initials: R
authors.lastname: Fischer-Betz
authors.forename: F
authors.initials: F
authors.lastname: Hiepe
mesh_terms: D005858:Germany; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D009173:Mycophenolic Acid / Q000008:administration & dosage / Q000031:analogs & derivatives*; D012219:Rheumatology / Q000592:standards*
chemical_list: D007166:Immunosuppressive Agents; D009173:Mycophenolic Acid